Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.70 |
| ▸ | DPP4 | P27487 | 4/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.69 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.69 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.69 |
| ▸ | FAP | Q12884 | 2/20 | 0.69 |
| ▸ | LTA4H | P09960 | 5/20 | 0.63 |
| ▸ | TACR1 | P25103 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900809 | 1.00 | ACE (0.70) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL29666849 | 1.00 | ACE (0.70) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL4330942 | 1.00 | ACE (0.70) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL3726263 | 1.00 | ACE (0.70) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL31026624 | 1.00 | ACE (0.70) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL7375090 | 1.00 | ACE (0.70) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL3726264 | 1.00 | ACE (0.70) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL6373910 | 0.99 | ACE (0.69) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL2879742 | 0.96 | ACE (0.65) | ACEDPP4DPP8DPP9DPP7 | |
| SCHEMBL2879744 | 0.96 | ACE (0.65) | ACEDPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | ACE 234/4885DPP4 1413/4885DPP8 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.